New BD FACSDiscover™ S8 Cell Sorters to Enable More Researchers to Push the Boundaries of Discovery
FRANKLIN LAKES, N.J., April 5, 2024 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
Using the FACSDiscover™ S8 Cell Sorters, researchers can confirm complex biological and spatial insights in real time, obtain individual cell images and isolate desired cells based on visual characteristics at high speeds, all within a simplified and easy to use workflow.
The new BD FACSDiscover™ S8 Cell Sorters feature BD CellView™ Image Technology, profiled on the cover of the journal Science in 2022, and BD SpectralFX™ Technology — bringing to market breakthrough innovations in real-time imaging and spectral flow cytometry. The three- and four-laser additions to the BD FACSDiscover™ S8 Cell Sorter family complement the five-laser instrument launched last year and provide scientists greater access, options, and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.
“For my research in cellular biology, the instrument was perfectly configured when it came to number of lasers and imaging capabilities,” said Daniel Schraivogel, Ph.D., a research staff scientist at EMBL, who estimates he had 600 hours working on the three-laser prototype. “It has the same sorting speed and software capabilities as the five-laser unit, making experiments extremely scalable on an easy-to-use instrument.”
Using the FACSDiscover™ S8 Cell Sorters, researchers can confirm complex biological and spatial insights in real time, obtain individual cell images and isolate desired cells based on visual characteristics at high speeds, all within a simplified and easy to use workflow. BD CellView™ Image Technology improves sort and sample quality, bringing confidence to biological results and saving researchers time and cost in their downstream applications. This expedited time to insight expands capabilities for researchers to transform research and cell-based therapeutic development across numerous fields in drug discovery, immuno-oncology and genomics.
“In flow cytometry, there are often ‘suspect’ populations where cells are dead or dying, and doublets and cellular debris that can impact the integrity of experiments,” Schraivogel continued. “In addition to the added value of spatial information that is needed for many projects in cell biology, infection biology and functional genomic screening, the imaging sorter allows us to better explore our cell populations and is used to validate true single-cell gating and sorting, to deliver better-quality cells and biological outputs.”
The family of BD FACSDiscover™ Cell Sorters will be featured at upcoming conferences beginning with the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, and is now available to order through local sales representatives. More information is available at bdbiosciences.com/S8.
About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
|
Contacts: |
|
|
Media: |
Investors: |
|
Troy Kirkpatrick |
Adam Reiffe |
|
VP, Public Relations |
Sr. Director, Investor Relations |
|
858.617.2361 |
201.847.6927 |
SOURCE BD (Becton, Dickinson and Company)
